Genetic alterations in benign, preneoplastic and malignant breast lesions

被引:3
作者
Kabalar, Mehmet Esref [2 ]
Karaman, Ali [1 ]
Aylu, Belkis [3 ]
Ozmen, Sevilay Akalp [2 ]
Erdem, Ilknur [2 ]
机构
[1] Erzurum Nenehatun Obstet & Gynecol Hosp, Dept Med Genet, TR-25070 Erzurum, Turkey
[2] Erzurum Training & Res Hosp, Dept Pathol, Erzurum, Turkey
[3] Erzurum Training & Res Hosp, Dept Gen Surg, Erzurum, Turkey
关键词
Breast cancer; breast precancerous lesions; micronucleus test; c-erb2; gene; bcl-2; BCL-2 PROTEIN EXPRESSION; CANCER PATIENTS; DNA-REPAIR; CHROMOSOMAL RADIOSENSITIVITY; C-ERBB-2; EXPRESSION; MONOCLONAL-ANTIBODY; DUCTAL CARCINOMA; IN-SITU; RECEPTOR; CHEMOTHERAPY;
D O I
10.4103/0377-4929.101737
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Context: The c-erbB-2 proto-oncogene is a member of the epidermal growth factor receptor family and has been associated with a more aggressive breast tumor biology and resistance to some types of treatments. Aims: The aim is to investigate the correlation among bcl-2 and c-erbB-2 and the micronucleus (MN) formation in patients with early breast cancer (BC). Materials and Methods: This study was conducted between May 2010 and December 2011. We analyzed the MN frequencies in 15 patients with invasive breast carcinoma (IBC), 13 patients with intraductal proliferative lesion (IDPL) and 12 benign breast lesion (BBL). The sample consisted of 40 formalin-fixed, paraffin-embedded blocks of benign and malignant breast tissue. The specimens were evaluated for bcl-2 or c-erbB-2 immunoreactivity was semi-quantitatively evaluated in at least 1000 cells examined under the microscope at 40x magnification and recorded as the percentage of c-erbB-2 and bcl-2 positive tumor cells over the total number of cells examined in the same area. The percentage scores were subsequently categorized using the 5% cut-off point for positive staining. Results: The MN was significantly increased in IBC and in IDPL patients compared to BBL patients (3.82 +/- 0.17 and 2.37 +/- 0.52, respectively, vs. 1.61 +/- 0.40, P < 0.001). On other hand, the MN frequencies in IBC patients were higher than those in IDPL patients (3.82 +/- 0.17 vs. 2.37 +/- 0.52, P < 0.01). c-erbB-2, had the highest record in IBC (60%), and the score was not observed in both IDPL and BBL: bcl-2 immunostaining was also assessed, the lowest recorded score was in IBC (46.66%) and the highest in both BBL and IDPL (100%). Furthermore, there was a significantly difference in the mean MN frequency between c-erbB-2 positive IBC patients (4.06 +/- 0.48) and c-erbB-2 negative IBC patients (3.44 +/- 0.39) (P < 0.05). Conclusions: Our results suggest that increased chromosome / DNA instabilities may be associated with the pathogenesis of early BC.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 59 条
[1]  
ANDERSON DE, 1992, CANCER-AM CANCER SOC, V70, P1740, DOI 10.1002/1097-0142(19920915)70:4+<1740::AID-CNCR2820701615>3.0.CO
[2]  
2-1
[3]  
Antunes Andreia, 2004, Acta Med Port, V17, P271
[4]  
Baeyens A, 2005, ONCOL REP, V13, P347
[5]   Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition [J].
Baeyens, A ;
Thierens, H ;
Claes, K ;
Poppe, B ;
Messiaen, L ;
De Ridder, L ;
Vral, A .
BRITISH JOURNAL OF CANCER, 2002, 87 (12) :1379-1385
[6]   Validation of biomarkers as early predictors of disease [J].
Bonassi, S ;
Neri, M ;
Puntoni, R .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2001, 480 :349-358
[7]   An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans [J].
Bonassi, Stefano ;
Znaor, Ariana ;
Ceppi, Marcello ;
Lando, Cecilia ;
Chang, Wushou Peter ;
Holland, Nina ;
Kirsch-Volders, Micheline ;
Zeiger, Errol ;
Ban, Sadayuki ;
Barale, Roberto ;
Bigatti, Maria Paola ;
Bolognesi, Claudia ;
Cebulska-Wasilewska, Antonina ;
Fabianova, Eleonora ;
Fucic, Alexandra ;
Hagmar, Lars ;
Joksic, Gordana ;
Martelli, Antonietta ;
Migliore, Lucia ;
Mirkova, Ekaterina ;
Scarfi, Maria Rosaria ;
Zijno, Andrea ;
Norppa, Hannu ;
Fenech, Michael .
CARCINOGENESIS, 2007, 28 (03) :625-631
[8]   Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index [J].
Callagy, GM ;
Pharoah, PD ;
Pinder, SE ;
Hsu, FD ;
Nielsen, TO ;
Ragaz, J ;
Ellis, IO ;
Huntsman, D ;
Caldas, C .
CLINICAL CANCER RESEARCH, 2006, 12 (08) :2468-2475
[9]   Chromosomal instability in MYH- and APC-mutant adenomatous polyps [J].
Cardoso, J ;
Molenaar, L ;
de Menezes, RX ;
van Leerdam, M ;
Rosenberg, C ;
Möslein, G ;
Sampson, J ;
Morreau, H ;
Boer, JM ;
Fodde, R .
CANCER RESEARCH, 2006, 66 (05) :2514-2519
[10]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648